John Hohneker
Director/Board Member at CARISMA THERAPEUTICS, INC.
Net worth: - $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| James Dentzer | M | 57 | 8 years | |
| Diantha Duvall | F | 52 | 2 years | |
| Hans Jörg Reinhardt | M | 68 | 40 years | |
| Volker Herrmann | M | - |
Sonata Therapeutics, Inc.
 Sonata Therapeutics, Inc. BiotechnologyHealth Technology Sonata Therapeutics, Inc. is a pioneering private company based in Cambridge, MA that designs single therapeutics to reprogram diseased cells and create curative microenvironments. The company's machine learning-based platform identifies novel insights, targets, and therapeutics across a wide range of disease areas, with a growing pipeline of small molecule drugs and genetic therapeutics. In oncology, Sonata's transformative therapies reprogram cancer cells to release curative signals that reverse immune cell suppression and blockade, empowering the immune system to holistically eradicate tumors and drive cure. Sonata Therapeutics is creating a new class of network medicines™ designed to modulate all the key cell types in a disease microenvironment required to drive disease resolution. The company is also exploring additional therapeutic areas such as fibrosis and tissue regeneration where multicellular networks play a key role. The company has subsidiaries in the United States. The company was founded in 2022 by flagship pioneering, and the CEO is Volker Herrmann. | - |
| Richard Morris | M | 51 | 3 years | |
| Zheng Bin Yao | M | 58 | 3 years | |
| Anil Singhal | M | 72 |
Trishula Therapeutics, Inc.
 Trishula Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021. | 3 years |
| Robert Martell | M | 61 | 13 years | |
| Stuart Lutzker | M | 63 | 3 years | |
| Martyn Greenacre | M | 82 | 24 years | |
| Steven Kelly | M | 59 | 6 years | |
| Bill Winters | M | 62 | 11 years | |
| Nancy Andrews | M | 65 | 9 years | |
| Eric Siegel | M | 60 | 1 years | |
| Samir Shah | M | 63 | 20 years | |
| Anne Borgman | M | 56 | 2 years | |
| Winston Kung | M | 48 | - | |
| Karah Parschauer | F | 46 | 7 years | |
| Jim Kastenmayer | M | 52 | 1 years | |
| Michael Torok | M | 45 | 1 years | |
| Charles Sawyers | M | 65 | 11 years | |
| Briggs Morrison | M | 65 | 4 years | |
| Michael Klichinsky | M | 34 | 8 years | |
| Marc Rubin | M | 69 | 14 years | |
| Vasant Narasimhan | M | 48 | 19 years | |
| Regina Hodits | M | 53 | 6 years | |
| Bahija Jallal | M | 62 | 2 years | |
| Jonathan Zung | M | 59 | 3 years | |
| Carl Gordon | M | 59 | 2 years | |
| Björn Ingemar Odlander | M | 66 | 2 years | |
| Sanford Zweifach | M | 68 | 3 years | |
| Scott Clarke | M | - |
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021. | 4 years |
| James Healy | M | 59 | 1 years | |
| Christian Nolet | M | 67 | 1 years | |
| Kenneth Kaitin | M | 71 | 21 years | |
| Mark W. Noel | M | 65 | 23 years | |
| Dan Dan Dong | M | 40 | 3 years | |
| Luke Evnin | M | 60 |
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021. | - |
| Dora Ferrari | F | - | 3 years | |
| Mark D. Plinio | M | 57 | 3 years | |
| Kimberly Steinmann | M | - | 2 years | |
| Rachel Blasbalg | F | - | 20 years | |
| Maria Petrini | F | - | 1 years | |
| Simon Brown | M | - | 11 years | |
| Terry Shields | F | - | 1 years | |
| Tom Wilton | M | - | 5 years | |
| Yang Wang | M | - | 3 years | |
| Nancy Soohoo | F | - | 21 years | |
| Leonard Dove | M | 51 | 2 years | |
| Nina Kjellson | F | 49 |
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021. | 4 years |
| Reinhard von Roemeling | M | - | 5 years | |
| Scott Brun | M | 56 |
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021. | - |
| Harry Werner Kirsch | M | 59 | 21 years | |
| David Scadden | M | 71 |
Sonata Therapeutics, Inc.
Sonata Therapeutics, Inc. BiotechnologyHealth Technology Sonata Therapeutics, Inc. is a pioneering private company based in Cambridge, MA that designs single therapeutics to reprogram diseased cells and create curative microenvironments. The company's machine learning-based platform identifies novel insights, targets, and therapeutics across a wide range of disease areas, with a growing pipeline of small molecule drugs and genetic therapeutics. In oncology, Sonata's transformative therapies reprogram cancer cells to release curative signals that reverse immune cell suppression and blockade, empowering the immune system to holistically eradicate tumors and drive cure. Sonata Therapeutics is creating a new class of network medicines™ designed to modulate all the key cell types in a disease microenvironment required to drive disease resolution. The company is also exploring additional therapeutic areas such as fibrosis and tissue regeneration where multicellular networks play a key role. The company has subsidiaries in the United States. The company was founded in 2022 by flagship pioneering, and the CEO is Volker Herrmann. | - |
| Daniel Cushing | M | - | 7 years | |
| Robin LaChapelle | F | 51 | 1 years | |
| Shalini Sharp | F | 49 | 7 years | |
| Linda Armstrong | M | 61 | 17 years | |
| Shelley Chu | M | 54 |
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021. | - |
| Douglas Cole | M | 63 |
Sonata Therapeutics, Inc.
Sonata Therapeutics, Inc. BiotechnologyHealth Technology Sonata Therapeutics, Inc. is a pioneering private company based in Cambridge, MA that designs single therapeutics to reprogram diseased cells and create curative microenvironments. The company's machine learning-based platform identifies novel insights, targets, and therapeutics across a wide range of disease areas, with a growing pipeline of small molecule drugs and genetic therapeutics. In oncology, Sonata's transformative therapies reprogram cancer cells to release curative signals that reverse immune cell suppression and blockade, empowering the immune system to holistically eradicate tumors and drive cure. Sonata Therapeutics is creating a new class of network medicines™ designed to modulate all the key cell types in a disease microenvironment required to drive disease resolution. The company is also exploring additional therapeutic areas such as fibrosis and tissue regeneration where multicellular networks play a key role. The company has subsidiaries in the United States. The company was founded in 2022 by flagship pioneering, and the CEO is Volker Herrmann. | - |
| Thomas Kassberg | M | 63 | 7 years | |
| Meghna Chowdary | F | - | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Timothy Morris | M | 62 | 6 years | |
| William Steinkrauss | M | 39 | 6 years | |
| Ronen Tamir | M | 57 | - | |
| David Epstein | M | 62 | 6 years | |
| Annalisa Jenkins | M | 58 | 3 years | |
| Wendelin Wiedeking | M | 72 | 11 years | |
| Ann Thorell | F | 56 | 1 years | |
| Jean Franchi | F | 57 | 2 years | |
| Rolf M. Zinkernagel | M | 80 | 15 years | |
| Christine Bellon | M | 59 |
FORMA Therapeutics, Inc.
 FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | 2 years |
| Ulrich Lehner | M | 78 | 13 years | |
| Lord Darzi | M | 63 | 5 years | |
| Joseph Jimenez | M | 64 | 11 years | |
| Eric Zhang | M | 43 | 5 years | |
| Karoline Shair | M | - |
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | 1 years |
| Peter Kornicker | M | - | 20 years | |
| Dimitri Azar | M | 65 | 7 years | |
| Tonya Williams | F | 50 | 1 years | |
| Dirk van de Put | M | 63 | 1 years | |
| Susanne Antonie Schaffert | M | 57 | 2 years | |
| Verena A. Briner | M | 72 | 3 years | |
| David Perry | M | 56 | 6 years | |
| Shannon Klinger | M | 53 | 10 years | |
| Chidozie Ugwumba | M | 41 | 4 years | |
| Rudy Howard | M | 67 | 2 years | |
| Amato Giaccia | M | 65 | 6 years | |
| Lori Kunkel | M | 66 | 6 years | |
| Jürgen Brokatzky-Geiger | M | 72 | 14 years | |
| Nancy Simonian | M | 63 | 3 years | |
| Srikant T. Madhav Datar | M | 70 | 18 years | |
| Yi Li Xie | M | 54 | 2 years | |
| Alexandre F. Jetzer-Chung | M | 83 | 15 years | |
| Michael Rogers | M | 64 | 4 years | |
| William Brody | M | 80 | - | |
| Ann Marie Fudge | F | 72 | - | |
| Theo Melas-Kyriazi | M | 64 | 6 years | |
| George Migausky | M | 69 | 2 years | |
| Gary Sutton | M | - | 13 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 74 | 74.00% |
| Switzerland | 26 | 26.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- John Hohneker
- Personal Network
